


2008 Fact Book



**Abbott**  
A Promise for Life

Founded in 1888 by Dr. Wallace C. Abbott, a Chicago physician, Abbott is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritional products for children and adults, and medical products, including devices, diagnostic tests and instruments.

Headquartered in north suburban Chicago, Abbott employs more than 68,000 people and markets its products in more than 130 countries.

- 2 Financial Highlights
- 4 Market-Leading Positions and Abbott's Leading Brands
- 5 Rankings
- 6 Pharmaceuticals
- 10 Nutritional Products
- 14 Medical Products
- 16 Medical Products – Diagnostics
- 17 Medical Products – Diabetes Care
- 17 Medical Products – Molecular Diagnostics
- 18 Medical Products – Point of Care
- 18 Medical Products – Vascular
- 19 Medical Products – Spine
- 19 Medical Products – Animal Health
- 20 History
- 23 Advancing Global Citizenship
- 26 Five-Year Financial Summary
- 28 Plant Locations
- 28 Directors
- 29 Senior Management and Corporate Vice Presidents

Abbott is focused on advancing patient care by developing innovative solutions in pharmaceuticals, diagnostics, medical devices and nutritional products.

Balanced • Global • Strong




# Financial Highlights

In 2007, Abbott reported sales and income from ongoing operations of \$25.9 billion and \$4.4 billion, respectively. Abbott also recorded its 336th consecutive quarterly dividend to be paid to shareholders since 1924. In addition, 2007 marked the 35th straight year Abbott's dividends have increased. The company's Pharmaceuticals business generated sales of more than \$14 billion. The Nutritional Products business generated sales of more than \$4 billion. The Medical Products business – which includes Animal Health, Diabetes Care, Diagnostics, Molecular Diagnostics, Point of Care, Spine, and Vascular businesses – generated more than \$6 billion in sales.

Abbott's leadership positions in several multi-billion-dollar businesses provide a unique balance of revenue, growth opportunities and cash flow sources that allow the company to invest in its future. In 2007, to further strengthen its business and sustain its success, Abbott invested more than \$2.5 billion in research and development. During 2007, Abbott's operating cash flow was \$5.2 billion.


## Sales by Major Operating Segment\*

(dollars in billions)




## Sales by Geography\*\*

(dollars in billions)



## Cash Dividends per Share

(dollars per share)



\* Excludes \$0.6 billion of other sales.

\*\* Sales excluding Boehringer Ingelheim products.

# Market-Leading Positions and Abbott's Leading Brands

Pharmaceuticals

Nutritional Products

Medical Products

## Anti-Infectives

*Klacid/Klaricid*  
(outside the U.S.)

## Cholesterol Management

*Niaspan*  
*Simcor*  
*TriCor*

## Immunology

*Humira*

## Inhalation Anesthetics

*Ultane/Sevorane*  
*SevoFlo*

## Neurological Treatments

*Depakote ER/*  
*Depakote*

## Protease Inhibitors for HIV

*Kaletra*  
*Norvir*

## Renal Care

*Zemplar*

## Thyroid Hormone Replacement

*Synthroid*

## Adult Nutrition

*EAS*  
*Ensure*  
*Glucerna*  
*ZonePerfect*

## Pediatric Nutrition

*Similac Advance*  
*Similac Alimentum*  
*Gain Advance*  
(outside the U.S.)  
*Gain Plus Advance*  
(outside the U.S.)  
*Gain Kid* (outside the U.S.)  
*Isomil Advance*  
*PediaSure*  
*PediaSure Complete*  
(outside the U.S.)

## Blood Screening

*Abbott Prism*  
system  
Viral screening reagents

## Carotid Artery Disease

*Acculink/Accunet*  
carotid stent platform  
*Xact/Emboshield*  
carotid stent platform

## Coronary Devices

*Hi-Torque Balance*  
*MiddleWeight*  
guidewire

## Coronary Stents

*Multi-Link Vision*  
*Multi-Link Mini Vision*  
*Xience V* (outside the U.S.)

## Glucose Monitoring

*FreeStyle Flash*  
(*FreeStyle Mini* outside the U.S.)  
*Precision Xtra*  
(*Precision Optium/Xceed* outside the U.S.)  
*Precision PCx*  
*AlphaTRAK*

## Hematology Diagnostics

*CELL-DYN* system and reagents

## Immunoassay Testing

*Architect* and *AxSYM* systems  
Automated diagnostic instruments

## Vessel Closure Devices

*StarClose*  
*Perclose* products

# Rankings

Abbott is ranked among the top companies in the world for financial strength and workplace excellence by leading national publications, including:

<b>Fortune</b>	Ranked 4th among the "Most Admired Companies" in the pharmaceutical sector.  Ranked 102nd on the <i>Fortune 500</i> list of the largest U.S.-based corporations (ranked by 2006 revenue).
<b>DiversityInc</b>	Named one of the "Top 50 Companies for Diversity."
<b>Forbes</b>	Ranked 167th on the <i>Forbes 2000</i> list (ranked by 2007 sales, profits, assets and market value).
<b>BusinessWeek</b>	Named one of the "Best Places to Launch a Career."
<b>Working Mother</b>	Named one of the "100 Best Employers for Working Mothers."
<b>Science</b>	Listed among the top 20 employers for scientists in a ranking of the world's most respected biotechnology and pharmaceutical companies.

Pharmaceuticals • Abbott is advancing science to develop effective treatments that can make a difference in patients' lives. We also continue to pursue new therapeutic indications for existing medications that offer physicians and patients important treatment options.



Niaspan  
for cholesterol



Synthroid  
for thyroid disease



Humira  
for autoimmune diseases



TriCor  
for cholesterol



Zemiplar  
for chronic kidney disease



Kaletra /Aluvia  
for HIV

# Pharmaceuticals

Abbott is dedicated to discovering, developing and marketing breakthrough drugs that improve patient health. Abbott sells pharmaceutical products in several therapeutic areas.

**Anesthesia.** Provides inhalation anesthetic agents, neuromuscular blockers, sedatives and other analgesic pain therapies.

*Ultane, Sevoflurane (sevoflurane)* Inhalation anesthetic for both inpatient and outpatient procedures, for adult and pediatric use.

**Anti-Infectives.** Antibiotics for the treatment of respiratory infections and skin infections.

*Biaxin, Klacid, Klaricid (clarithromycin), Biaxin XL, Klaricid OD (clarithromycin extended-release formulation)* Oral macrolide antibiotic for the treatment of upper and lower respiratory tract infections. Clarithromycin is also used for skin and skin structure infections, treatment and prevention of *Mycobacterium avium* complex (MAC) and eradication of the ulcer-causing bacterium *H. pylori*.

*Erythromycin, PCE* Generic and polymer-coated macrolide antibiotic.

**Cardiovascular.** Includes anti-hypertensive medicines for reducing high blood pressure, treatment for congestive heart failure and medicine for managing high cholesterol and triglycerides.

*Blopress, Tiadyl (candesartan)* Angiotensin-2 antagonist for hypertension. (Marketed outside the United States.)

*Niaspan (niacin extended-release tablets), Simcor (Niaspan/simvastatin), TriCor (fenofibrate tablets)* Used along with diet and exercise to raise HDL, or "good" cholesterol, and lower LDL, or "bad" cholesterol, and to lower triglycerides.

*Simdax (levosimendan)* Injectable for acute congestive heart failure. (Marketed outside the United States.)

**Immunology.** Drugs used to treat some diseases of the immune system.

*Humira (adalimumab)* Self-injectable, fully human, monoclonal TNF-blocking treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and juvenile rheumatoid arthritis.

**Metabolics.** Includes medicines for the management of obesity and the treatment of thyroid disease.

*Meridia, Reductil (sibutramine hydrochloride monohydrate)* Serotonin and norepinephrine re-uptake inhibitor (SNRI) used with a reduced calorie diet for the management of obesity.

*Synthroid (levothyroxine sodium)* Synthetic thyroid hormone for the treatment of hypothyroidism and subclinical hypothyroidism.

**Neuroscience and Pain Care.** Drugs to treat neurological conditions, as well as medications for pain management.

*Depakote ER (divalproex sodium, extended-release tablets) Depakote, Epival, Valcote (divalproex sodium, enteric-coated tablets)* Anti-epileptic agent (adult/pediatric) also used for the treatment of the manic episodes of bipolar disorder and for the prevention of migraine headaches (adult).

*Dilaudid (hydromorphone hydrochloride)* Analgesic for moderate to severe pain.

**Pediatric and Neonatal.** Drugs for newborns with serious respiratory conditions.

*Survanta (beractant)* Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

*Synagis (palivizumab)* Monoclonal antibody for the prevention of serious respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV. (Marketed outside the United States.)

**Renal Care.** Includes oral and injectable activated vitamin D agents developed to treat patients with complications of chronic kidney disease.

*Zemplar (paricalcitol injection and capsules)* Therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.

**Urology and Reproductive Health.** Includes medicines for benign prostatic hyperplasia (BPH), advanced prostate cancer, endometriosis, anemia associated with uterine fibroids and central precocious puberty.

*Lupron Depot, Lucrin (leuprolide acetate for depot suspension)* Synthetic hormone for the treatment of advanced prostate cancer, endometriosis, preoperative treatment of anemia associated with uterine fibroid tumors in combination with iron, and central precocious puberty.

**Virology.** Drugs to treat HIV.

*Kaletra, Aluvia (lopinavir/ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

*Norvir (ritonavir)* Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

Nutritional Products • Abbott offers some of the world's most trusted brands of pediatric nutrition, adult nutrition, performance nutrition and nutritious snack products. We also provide specially formulated medical nutritional products for patients with unique dietary needs due to illness or injury.



Pediatric Nutrition



Adult Nutrition



Healthy Living

# Nutritional Products

Abbott is a leader in providing trusted pediatric and adult nutrition formulas, shakes, bars, snacks and tube feeding products to improve people's quality of life. Abbott Nutrition Products Division develops and markets nutritional products for the United States, while Abbott Nutrition International markets these products outside the United States.

**Pediatric Nutrition.** Abbott develops products that support the growth and development of infants and children and makes these products available in innovative, consumer-friendly packaging. Specialty formulations include products for premature and low-birth-weight infants and products for infants and children with special tolerance or nutritional needs.

<i>Gain Advance</i>	A nutritional supplement for children 6 months to 1 year old during the transition to solid foods. <i>Gain</i> contains the <i>Eye-Q</i> system of nutrients, nucleotides and increased levels of protein and energy to support brain development, the immune system and overall growth. (Marketed outside the United States.)
<i>Gain Plus Advance</i>	Nutritional choice for children 1 to 3 years old. The <i>Eye-Q</i> system is also available with <i>Gain Plus Advance</i> and it contains pre- and probiotics (synbiotics) to help support children's natural defenses. (Marketed outside the United States.)
<i>Gain Kid</i>	Growth-focused nutritional supplements for children 3 years old and beyond, delivering more than 30 essential nutrients. <i>Gain Kid</i> is also available with the <i>Eye-Q</i> system of nutrients. (Marketed outside the United States.)
<i>Isomil Advance</i>	A broad line of soy-based formulas for infants and toddlers with common feeding problems such as fussiness, gassiness and spitting-up.
<i>NutriPals</i>	A line of bars and shakes for children that provide a good source of more than 20 essential vitamins and minerals plus protein in a take-along snack.
<i>Pedialyte</i>	Oral electrolyte maintenance solution to help prevent dehydration by quickly replacing fluids and electrolytes lost during diarrhea and vomiting. Also available as <i>Pedialyte Freezer Pops</i> and <i>Pedialyte Singles</i> .
<i>PediaSure and PediaSure Complete</i>	Complete, balanced nutritional formula in a variety of flavors for children 1 to 10 years old. Available with fiber, as an oral supplement and in a tube feeding formulation. <i>PediaSure Complete</i> contains synbiotics.
<i>Similac Advance</i>	A complete line of infant and toddler formulas that offer DHA, ARA and a patented blend of nucleotides to help support healthy development of the eyes, brain and immune system. The line also includes highly specialized products to meet the unique needs of premature and low-birth-weight babies, including <i>Similac Human Milk Fortifier</i> , <i>Similac Special Care</i> and <i>Similac NeoSure</i> .
<i>Similac Alimentum</i>	A formula for infants with food allergies or colic due to protein sensitivity.
<i>Similac Sensitive and Similac Sensitive RS</i>	Lactose-free infant formulas indicated for mild gastrointestinal intolerance symptoms.
<i>Similac Organic</i>	The first major brand-name organic infant formula.

**Adult Nutrition and Healthy Living.** Abbott offers a broad selection of nutrition bars, shakes and related products that satisfy a wide range of consumer nutrition needs.

<i>EAS</i>	A leading brand of nutrition bars, shakes and dietary supplements designed to help active-lifestyle consumers meet their fitness, performance and endurance goals.
<i>Ensure</i>	A broad line of leading adult nutritional products, providing a source of complete, balanced nutrition to help consumers stay active, healthy and energetic. <i>Ensure</i> shakes are available in a variety of flavors and nutritional formulations.
<i>ZonePerfect</i>	A leading brand of convenient, surprisingly delicious nutritional bars designed to satisfy hunger through a unique balance of carbohydrates, protein and fat.

**Therapeutic Nutrition.** Abbott offers medical nutritionals and devices for patients with special dietary needs who require tube feeding or other nutritional interventions due to complex illness or injury. Abbott also offers specialized nutrition products for infants and children with multiple food allergies, severe gastrointestinal impairment or metabolic diseases.

<i>Companion, Flexiflo, Infinity, Patrol and Quantum</i>	Complete line of enteral feeding pumps, tubes and devices.
<i>Glucerna, Glucerna SR</i>	The first therapeutic nutritional product for people with diabetes or patients with impaired glucose tolerance. Available in shakes, meal bars, cereal, snack bars and tube feeding formulations. <i>Glucerna SR</i> (marketed outside the United States) is an advanced formulation to improve glycemic control and help people with diabetes achieve or maintain optimal weight management.
<i>EleCare</i>	Nutritional formula for infants and children with multiple food allergies or severe gastrointestinal impairment.
<i>Jevity</i>	Fiber-fortified liquid formula line available with various protein and caloric levels for both short- and long-term tube feeding.
<i>Oxepa and Pulmocare</i>	Specialized nutritional products for patients with respiratory conditions, including acute lung injury/acute respiratory distress syndrome ( <i>Oxepa</i> ) and pulmonary disease ( <i>Pulmocare</i> ).
<i>ProSure</i>	A clinically tested therapeutic nutritional product, specially designed to help people with cancer-induced weight loss to gain weight and strength and improve their quality of life. (Marketed outside the United States.)

Medical Products • Abbott is an innovative leader in the fast-paced, high-growth medical technology space. Our medical products are advancing disease diagnosis, diabetes management and the treatment of vascular disease.




Diabetes Care



Molecular  
Diagnostics



Diagnostics



Vascular

## Medical Products – Diagnostics

Abbott Diagnostics offers a broad range of innovative instruments and tests across key segments in the global diagnostics market, including hospitals, reference laboratories, blood banks, physicians' offices and clinics.

**Immunoassay and Clinical Chemistry.** Includes systems and assays to measure a variety of analytes found in the blood and to diagnose and monitor diseases and therapies. Also includes blood screening instrumentation and assays used to ensure the safety of the blood supply.

**Abbott Prism** Fully automated analyzer specifically designed for high-volume blood centers and blood banks to screen donated blood for multiple viral assays. Menu includes HIV, hepatitis and HTLV assays. (Not all assays are available in the United States.)

**AbbottLink** Software that transmits instrument performance information to Abbott's service operations through the Internet, enhancing the remote identification and rapid resolution of technical issues on select analyzers.

**Accelerator Automated Processing Systems** Automates the labor-intensive, repetitive motion in the laboratory. *Accelerator APS* improves process consistency, reduces dependency on manual labor and enhances overall operator safety.

**Accelerator Decision Manager** Software that provides connectivity and functionality across the entire laboratory, reducing turnaround time and labor dependency, while improving the quality of results.

**Aeroset, Architect c8000 and c16000** High- and medium-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty testing.

**Architect i2000, i2000<sub>SR</sub> and i1000<sub>SR</sub>** Modular analyzers that provide immunoassay testing. Menu includes tests for cancer, cardiovascular and thyroid disease, fertility, infectious disease and pregnancy.

**Architect ci8200, ci16200** Analyzers that integrate with the *Architect* clinical chemistry analyzers and the *i2000<sub>SR</sub>*, to provide a consolidated workstation to perform both clinical chemistry and immunoassay tests.

**AxSYM** Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular and thyroid disease, drugs of abuse, fertility, hepatitis and pregnancy.

**IMx** Automated benchtop analyzer for immunoassay testing. Menu includes tests for cardiovascular and thyroid disease, cancer and fertility.

**TDx and TDx Fix** Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline, vancomycin, drugs of abuse and thyroid tests.

**OraQuick Advance** Rapid, simple test for HIV type 1 and type 2. (Marketed in the United States under a distribution agreement with OraSure Technologies, Inc.).

**Hematology.** Abbott develops, manufactures and markets CELL-DYN hematology systems used to perform sophisticated blood cell analysis.

**CELL-DYN Ruby, 3700, 3200, 1800** A complete line of highly automated hematology analyzers to meet the testing needs of any laboratory, whether high or low volume.

**CELL-DYN Sapphire** A high-volume, automated hematology analyzer that incorporates monoclonal antibody tests, reducing the need for external sample analysis.

## Medical Products – Diabetes Care

Abbott Diabetes Care is committed to improving the lives of people with diabetes by providing innovative glucose monitoring systems that offer patients and health care professionals fast, convenient and accurate results.

**FreeStyle Flash Blood Glucose Monitoring System (FreeStyle Mini Blood Glucose Monitoring System outside the United States)** A small, discreet meter offering innovative features including a backlight display, four daily programmable alarms to remind patients to test, the world's smallest blood sample (0.3 microliter) and a 5-second average testing time.

**FreeStyle Freedom Lite Blood Glucose Monitoring System** An easy-to-hold, easy-to-read blood glucose monitoring system that uses a 0.3 microliter blood sample; has the most approved alternative sites for testing; features a 5-second average test time; and requires no coding for easy testing.

**FreeStyle Lite Blood Glucose Monitoring System** A blood glucose meter with a fixed calibration code feature that eliminates the manual coding step usually required by most blood glucose meters.

**FreeStyle Navigator Continuous Glucose Monitoring System** A new system that measures glucose levels once per minute, 24 hours a day, using a 5-day sensor, worn only on the back of the upper arm or on the abdomen, that wirelessly transmits readings to a pager-like device kept in a pocket or purse.

**Precision Xtra Blood Glucose and Ketone Monitoring System (Precision Optium/Xceed outside the United States)** A home-use meter capable of measuring both blood glucose and blood ketone levels.

**Precision PCx Point-of-Care System** A handheld, point-of-care blood glucose testing system, developed to meet the unique testing and data management needs in the hospital setting, that offers improved data communication speeds and an end-fill strip technology.

## Medical Products – Molecular Diagnostics

Abbott Molecular provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. Includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA.

**Abbott RealTime tests for HIV-1, HCV, HBV and CT/NG** Molecular tests for use on the *m2000* automated system, based on real-time PCR (polymerase chain reaction) technology. The tests are used to monitor hepatitis and HIV-1 viral loads and to diagnose chlamydia and gonorrhea infections. (Not all tests are available in the United States.)

**Abbott m2000** This system integrates sample preparation with real-time PCR amplification and detection technology to provide full automation, from sample extraction to the reporting of final patient results.

**m1000** An automated stand-alone instrument used to purify and extract RNA and DNA from patient samples using novel magnetic particle technology.

**PathVysion HER-2 DNA Probe Kit** Detects the HER-2 gene in breast cancer patients. Patients who have extra copies of this gene are candidates for treatment with Herceptin, a targeted monoclonal treatment.

**UroVysion** A DNA-based test for the initial diagnosis of patients with bladder cancer presenting with hematuria (blood in urine) or suspected of having bladder cancer, and the monitoring of bladder cancer recurrence. Detects genetic changes in bladder cells.

**ViroSeq HIV-1** Genotyping system used by physicians as an aid in monitoring and treating HIV infection. Designed to detect mutations in the HIV-1 virus that are associated with drug resistance. (Marketed by Abbott as part of its alliance with Celera Diagnostics.)

## Medical Products – Point of Care

Abbott Point of Care develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis. *i-STAT* technology provides physicians with the information they need to make lifesaving decisions in the intensive and acute care settings of the hospital.

<i>i-STAT System</i>	Offers a broad menu of tests for prognostic, diagnostic and treatment indicators related to disease state management and clinical practice guidelines to support a patient-centric approach to health care.
----------------------	---

## Medical Products – Vascular

Abbott Vascular markets a broad portfolio of coronary, endovascular and vessel closure technologies, used in the treatment of vascular disease.

### Biliary Self-Expanding Stent System

<i>Absolute Biliary Self-Expanding Stent System, Dynalink Biliary Self-Expanding Stent System</i>	Biliary self-expanding systems used to treat malignant strictures in the bile duct.
---	---

<i>Herculink Elite Biliary Balloon Expandable Stent System, OMNILINK Biliary Balloon Expandable Stent System</i>	Biliary balloon expandable stent systems used to treat malignant strictures in the bile duct.
--	---

<i>Xceed Biliary Self-Expanding Stent System, Xpert Biliary Self-Expanding Stent System</i>	Biliary self-expanding stent systems designed to treat malignant strictures/neoplasms in the bile duct.
---	---

### Carotid

<i>Acculink, AccUNET</i>	The <i>Acculink</i> carotid stent is a conformable self-expanding nitinol stent available on a rapid exchange delivery system. It is used with the <i>AccUNET</i> system, a filter with a nitinol basket to capture plaque fragments (emboli) that may be dislodged during the carotid stenting procedure.
--------------------------	--

<i>Xact, Emboshield</i>	<i>Xact</i> is a self-expanding stent designed specifically for use in the carotid arteries of the neck that carry blood to the brain. <i>Emboshield</i> is a filter used to capture emboli that may be dislodged during carotid stenting procedures.
-------------------------	---

### Coronary

<i>ASAHI guidewires</i>	A full product line of guidewires that facilitate access to diseased vessels and allow the clinician to thread interventional devices to the most difficult-to-reach areas of the vasculature.
-------------------------	--

<i>HI-TORQUE guidewires</i>	A full line of coronary guidewires to assist the interventional cardiologist in accessing treatment areas.
-----------------------------	--

<i>VOYAGER balloons</i>	A line of coronary balloons enabling the potential for superb stent expansion in the arteries surrounding the heart.
-------------------------	--

<i>Multi-Link Vision, Multi-Link Mini Vision stent</i>	Thin-strut metallic stents based on cobalt chromium technology for coronary obstructions from either 2.0 mm to 2.5 mm or 3.0 mm to 4.0 mm.
--	--

<i>Xience V stent system</i>	A next-generation drug-eluting coronary stent system developed on the <i>Multi-Link Vision</i> platform. The <i>Xience V</i> stent system combines the cobalt chromium stent with everolimus to treat coronary obstructions and prevent post-procedure vessel renarrowing. (Approved and marketed only outside the United States.)
------------------------------	--

### Vessel Closure

<i>Perclose A-T, ProStar</i>	Suture-mediated vessel closure devices designed to expedite recovery following diagnostic or interventional catheterization procedures.
------------------------------	---

<i>StarClose</i>	Vascular closure device that features a flexible nitinol clip to enable secure extravascular closure of the femoral artery access site in diagnostic or interventional catheterization procedures.
------------------	--

## Medical Products – Spine

Abbott Spine designs, develops and distributes devices and systems for spine surgery. Using our products, surgeons treat patients with a variety of diseases, traumatic injuries and deformities of the neck and mid to low back. Abbott Spine is known for its technical expertise and industry-leading training programs for surgeons.

### Minimally Invasive Systems

<i>PathFinder</i>	A minimally invasive system used in lower-back surgery requiring only two small incisions, potentially reducing post-operative pain and allowing patients to leave the hospital more quickly.
-------------------	---

### Thoracolumbar Systems

<i>Universal Clamp</i>	Helps surgeons correct patient spine deformities like scoliosis.
------------------------	--

<i>InCompass</i>	An implant system designed for the mid and lower back to promote stability and fusion of the vertebrae.
------------------	---

### Cervical and Cervicothoracic Systems

<i>SC-AcuFix</i>	A comprehensive line of implants and instrumentation that stabilizes the neck to promote spinal fusion.
------------------	---

<i>Nex-Link</i>	An implant system used in the back of the neck to stabilize the neck and higher segments of the spine.
-----------------	--

### Emerging Technologies

<i>Wallis System</i>	A device implanted in the lower back that helps back pain and other symptoms without requiring a fusion procedure. (Approved and marketed only outside the United States.)
----------------------	--

## Medical Products – Animal Health

Abbott Animal Health is a leader in perioperative health care for the veterinary market. Products include anesthetic and wound care products, nutritionals, a complete line for IV fluid therapy and other veterinary critical care products.

<i>AlphaTRAK Blood Glucose Monitoring System</i>	A blood glucose monitoring system specifically calibrated and validated for dogs and cats that provides veterinarians fast, inexpensive, convenient and, most important, accurate blood glucose results.
--	--

<i>PropoFlo (propofol)</i>	A versatile intravenous anesthetic characterized by rapid and smooth inductions and recoveries.
----------------------------	---

<i>SevoFlo (sevoflurane)</i>	An inhalant anesthetic that provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.
------------------------------	--

<i>Nexaband S/C Adhesive</i>	A medical-grade tissue adhesive that can be used instead of sutures and staples to close incisions. It provides a strong, flexible barrier during healing and eases away naturally within seven to 10 days.
------------------------------	---

**A tradition of innovation.**

For 120 years, Abbott has been a pioneer in developing innovative solutions that improve health and the practice of health care. In 1888, 30-year-old Wallace C. Abbott, M.D., began making a new form of medicine. Using the active – or alkaloid – part of a medicinal plant, he formed tiny pills, called “dosimetric granules,” which provided a measured amount of the drug. The demand for these accurate granules soon far exceeded the needs of his own practice. From a small operation based above Dr. Abbott’s pharmacy, Abbott has evolved into one of the world’s leading health care companies.

**1888** Dr. Abbott begins producing dosimetric granules in his apartment on Chicago’s North Side.

**1900** The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.

**1915** The company changes its name to Abbott Laboratories.

**1920** Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Ill.

**1929** Abbott stock is listed on the Chicago Stock Exchange. The offering is 20,000 shares for \$32 each.

**1931** Abbott establishes its first international affiliate in Montreal, Canada. The company’s international presence will grow steadily.

**1936** Abbott introduces the anesthetic agent Pentothal, developed by Abbott scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they are named to the U.S. Inventors Hall of Fame in 1986.

**1941** Abbott is one of the five pioneers in the United States to start commercial production of penicillin.

**1952** Erythrocin, a new antibiotic with good activity against gram-positive bacteria, is introduced.

**1962** Abbott enters a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals. Major plant expansions are completed in England, Italy and France.

**1964** The company acquires M&R Dietetic Laboratories of Columbus, Ohio, which eventually becomes Abbott’s Ross Products Division.

**1965** Abbott moves major operations to Abbott Park, a 420-acre site southwest of its North Chicago headquarters.

**1973** Abbott forms its diagnostics division to bring together all diagnostic products and services. The company also introduces *Ensure*, the first adult medical nutritional.

**1977** TAP Pharmaceuticals, now known as TAP Pharmaceutical Products Inc., is formed as a joint venture between Abbott and Takeda Chemical Industries, Ltd. of Japan.

**1983** *Depakote*, a new treatment for epilepsy, is approved in the United States.

**1985** Abbott wins U.S. approval to market the world’s first diagnostic test for AIDS. TAP receives approval for *Lupron*, a new therapy for prostate cancer.

**1987** *Hytrin*, a new cardiovascular drug for the treatment of hypertension, receives FDA approval.

**1988** Abbott celebrates its centennial. The *IMx* immunoassay system is introduced and goes on to become one of the best-selling new products in Abbott’s history.

**1990** *Biaxin*, an important new macrolide antibiotic, is introduced.

**1991** Several major products are introduced worldwide, including *Survanta*, for the treatment of neonatal respiratory distress syndrome. Abbott enters the hematology testing market with the acquisition of Sequoia-Turner Corp.

**1993** *Hytrin* receives FDA clearance for use in treating symptoms of benign prostatic hyperplasia, a condition of the prostate. Abbott launches *AxSYM*, a new, labor-saving diagnostic system.

**1994** Abbott introduces sevoflurane, the first truly universal anesthetic, and completes an agreement to cross-license LCR and PCR, two gene amplification technologies.

**1995** TAP receives approval for *Prevacid*, a proton pump inhibitor used in treating ulcers. *Abbott Prism*, the first fully automated, high-volume blood analyzer, is introduced outside the United States.

**1996** The company receives FDA approval for *Norvir*, a protease inhibitor for the treatment of HIV and AIDS. The company enters the glucose testing market with its acquisition of MediSense, Inc.

**1997** Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc., and also launches several new products, including an improved version of *Similac* infant formula in the United States.

**1998** Abbott launches *Glucerna* shakes and snack bars, specially formulated nutritionals for people with diabetes. *Depakote* surpasses lithium as the most-prescribed drug for treating mania. Abbott launches several pharmaceutical products, including *Zemplar*, *TriCor* and *Synagis*.

- 1999** Abbott launches *Architect*, a next-generation diagnostic system, and acquires Perclose, Inc., a leading vascular closure devices company.
- 2000** Abbott receives FDA approval for several new drugs or new formulations, including *Kaletra* (an advanced-generation protease inhibitor for the treatment of HIV/AIDS), *Biaxin XL* (a once-daily version of its flagship antibiotic) and *Depakote ER* (for migraine prevention).
- 2001** Abbott completes the acquisition of the pharmaceutical business of BASF, including the global operations of Knoll Pharmaceuticals. In addition, Abbott acquires Vysis, Inc., a leading genomic disease management company.
- 2002** Abbott receives FDA approval for *Humira* (for rheumatoid arthritis) and *Synthroid* (for hypothyroidism). The company launches *Similac Advance*, *Isomil Advance* and *NeoSure Advance* infant formulas in the United States. Abbott acquires the cardiovascular stent business of Biocompatibles International plc.
- 2003** Abbott launches three new immunodiagnosics systems on the *Architect* platform. Abbott receives European regulatory approval for *Humira* to treat rheumatoid arthritis. Abbott acquires JOMED's coronary and peripheral intervention business lines, Spinal Concepts Inc., ZonePerfect Nutritional Co., and Integrated Vascular Systems Inc.
- 2004** Abbott acquires TheraSense Inc., a leading blood glucose monitoring business, as well as i-STAT Corp., EAS Inc., and Spine Next S.A. Abbott creates Hospira, an independent, publicly traded company. Hospira is one of the largest global specialty pharmaceutical and medication delivery companies serving the hospital market.
- 2005** Abbott introduces several medical devices, including the *Xact/Emboshield* carotid stent system, *StarClose* vascular closure device and, in the United States, diagnostic devices *Abbott Prism* and *CELL-DYN Sapphire*. Abbott also receives FDA approval for two new indications for *Humira* (psoriatic arthritis and early rheumatoid arthritis).
- 2006** Abbott acquires the vascular business of Guidant Inc., a leader in coronary and vascular products, and Kos Pharmaceuticals, a specialty pharmaceutical company with a significant cholesterol management portfolio. Abbott also launches its drug-eluting stent, *Xience V*, outside the United States.
- 2007** Abbott submits a record number of major products for regulatory approval and launches *Humira* for Crohn's disease and *Niaspan* to treat cholesterol and triglycerides.

# Advancing Global Citizenship



In 2007, more than 100,000 children received nutritional assessments at Angkor Hospital for Children in Cambodia. Together with Abbott and the Abbott Fund, we are supporting family nutrition workshops that teach preparation of healthy foods made from locally available products.

# Advancing Global Citizenship

At Abbott, we believe that our right to do business entails a responsibility to society. We recognize that the sustainability of our company depends upon our ability to think and act for the long term for all the people we serve – most important, the patients who benefit from our medicines and technologies. From ethics and compliance to diversity and inclusion, from product quality to the environment, our commitment to good corporate citizenship is an integral part of who we are and how we conduct business. Through our programs, we engage and partner with many organizations in the pursuit of sustainable solutions to global challenges.

In recognition of the company's leading economic, social and environmental performance, Abbott was named to the Dow Jones Sustainability Index for the third straight year in 2007. For more information on our work, visit [www.abbott.com/citizenship](http://www.abbott.com/citizenship).

## **Improving Access to Health Care**

Improving access to affordable health care is one of the greatest challenges facing society, the health care industry and Abbott. A core part of our business strategy is to help ensure that those who can benefit from our medicines and medical products have access to them. We are committed to expanding access for patients by advancing leading-edge science and technology, increasing patient awareness about diseases and products, making our medicines available through company- and industry-run programs, and participating in public policy dialogue.

As part of these efforts, Abbott and its philanthropic foundation, Abbott Fund, invested more than \$380 million in grants and product donations to improve the lives of millions of people worldwide in 2007. This included providing product donations to support medical missions and other global humanitarian efforts in 98 countries. In the United States, Abbott provided 124,000 U.S. patients with free medicines, medical nutritional products and diabetes care products through the company's patient assistance programs.

## **Corporate Governance**

Abbott has a long tradition of ensuring the independence of the majority of our board of directors. All members of the public policy, audit, compensation, and nominations and governance committees are independent. Among the criteria for candidates of the board are a global business perspective and a commitment to good corporate citizenship. The charter of the board's public policy committee includes the review and evaluation of Abbott's policies and procedures with respect to social responsibility.

## **Ethics and Compliance**

Ethical conduct and compliance with the law are central to fulfilling our responsibilities to our patients, customers and shareholders. Making ethical decisions and acting responsibly is the job of every Abbott employee. The Office of Ethics and Compliance reinforces our company's commitment to promoting a culture of integrity and provides employees with resources on ethics and compliance issues. This includes the Abbott Code of Business Conduct, available in 35 languages; the Ethics and Compliance Helpline; division-level compliance staff; and a comprehensive in-person and Web-based training program.

## **Diversity and Inclusiveness**

Our employee population reflects the people who use our products, and we work to create an inclusive environment that enables all people to contribute to their full potential. This is reflected in our company's policies and practices, including hiring and advancement, leadership development and work-life benefits.

## **Environment, Health and Safety**

We conduct our business in a manner designed to be protective of human health, safety and the environment. We strive to be a leader in these areas by establishing performance goals and developing new strategies, standards and systems for continuous improvement. For example, in 2007, Abbott became the first Fortune 500 company to go carbon neutral with our entire U.S. sales vehicle fleet. The company also adopted an aggressive goal to reduce overall CO2 emissions by 30 percent by 2011, and invested in renewable energy projects including a new solar power system at the company's vascular plant in California. To view our energy policy and other EHS highlights, visit [www.abbott.com/citizenship/EHS](http://www.abbott.com/citizenship/EHS).

# Five-Year Financial Summary (a)

(dollars in millions, except per share data)

Year Ended December 31	2007	2006	2005	2004	2003
<b>Summary of Operations:</b>					
Net sales	\$25,914.2	22,476.3	22,337.8	19,680.0	17,280.3
Cost of products sold	\$11,422.0	9,815.1	10,641.1	8,884.2	7,774.2
Research and development (a)	\$ 2,505.6	2,255.3	1,821.2	1,696.8	1,623.8
Selling, general and administrative	\$ 7,408.0	6,349.7	5,496.1	4,921.8	4,808.1
Operating earnings	\$ 4,578.5	2,042.2	4,362.3	3,898.3	2,974.0
Interest expense	\$ 593.1	416.2	241.4	200.2	188.3
Interest income	\$ (136.8)	(123.8)	(87.7)	(51.1)	(41.9)
Other (income), net	\$ (347.5)	(526.5)	(411.3)	(376.4)	(559.5)
Earnings from continuing operations before taxes	\$ 4,469.6	2,276.4	4,619.9	4,125.6	3,387.2
Taxes on earnings from continuing operations	\$ 863.3	559.6	1,247.9	949.8	882.4
Earnings from continuing operations	\$ 3,606.3	1,716.8	3,372.1	3,175.8	2,504.7
Basic earnings per share from continuing operations	\$ 2.34	1.12	2.17	2.03	1.60
Diluted earnings per share from continuing operations	\$ 2.31	1.12	2.16	2.02	1.59
<b>Financial Position:</b>					
Working capital	\$ 4,939.5	(669.3)	3,970.5	3,908.8	2,650.9
Long-term investments	\$ 1,125.3	1,229.9	134.0	145.8	406.4
Net property and equipment	\$ 7,518.1	6,946.4	6,003.1	6,007.9	6,281.8
Total assets	\$39,713.9	36,178.2	29,141.2	28,767.5	26,039.3
Long-term debt	\$ 9,487.8	7,009.7	4,571.5	4,787.9	3,452.3
Shareholders' investment	\$17,778.5	14,054.2	14,415.3	14,325.8	13,072.3
Return on shareholders' investment from continuing operations	% 22.7	12.1	23.5	23.8	22.6
Book value per share	\$ 11.47	9.14	9.37	9.18	8.36
<b>Other Statistics:</b>					
Gross profit margin	% 55.9	56.3	52.4	54.9	55.0
Research and development to net sales	% 9.7	10.0	8.2	8.6	9.4
Net cash from operating activities of continuing operations	\$ 5,183.8	5,262.1	5,047.4	4,306.0	3,385.2
Capital expenditures	\$ 1,656.2	1,337.8	1,207.5	1,291.6	1,050.1
Cash dividends declared per common share	\$ 1.30	1.18	1.10	1.04	0.98
Common shares outstanding (in thousands)	1,549,910	1,537,243	1,539,235	1,560,024	1,564,518
Number of common shareholders	73,176	77,727	82,237	88,582	91,212
Number of employees	68,697	66,663	59,735	60,617	58,181
Sales per employee (in dollars)	\$ 377,225	337,163	373,948	324,662	297,010
Market price per share – high	\$ 59.50	49.87	50.00	47.63	47.15
Market price per share – low	\$ 48.75	39.18	37.50	38.26	33.75
Market price per share – close	\$ 56.15	48.71	39.43	46.65	46.60

(a) In 2006, 2005, 2004 and 2003 Abbott also recorded pretax charges of \$2,014, \$17, \$279 and \$100 respectively, for acquired in-process research and development related to business acquisitions.

## Plant Locations

The company's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400. The locations of the company's principal plants as of December 31, 2007, are listed below.

Abbott Park, Illinois	Longford, Ireland
Alameda, California	Ludwigshafen, Germany
Altavista, Virginia	Mexico City, Mexico
Barceloneta, Puerto Rico	North Chicago, Illinois
Brockville, Canada	Ottawa, Ontario, Canada
Campoverde di Aprilia, Italy	Redwood City, California
Casa Grande, Arizona	Rio de Janeiro, Brazil
Clonmel, Ireland	Santa Clara, California
Columbus, Ohio	Sligo, Ireland
Cootehill, Ireland	South Pasadena, California
Dartford, England	Sturgis, Michigan
Des Plaines, Illinois	Temecula, California
Edison, New Jersey	Whippany, New Jersey
Fairfield, California	Wiesbaden, Dekenheim, Germany
Granada, Spain	Witney, Oxon, England
Irving, Texas	Worcester, Massachusetts
Jayuya, Puerto Rico	Zwolle, the Netherlands
Katsuyama, Japan	

## Directors

Roxanne S. Austin <i>President, Austin Investment Advisors Newport Coast, Calif.</i>	W. Ann Reynolds, Ph.D. <i>Former President, The University of Alabama at Birmingham Birmingham, Ala.</i>
William M. Daley <i>Head of the Office of Corporate Social Responsibility and Chairman of the Midwest, JPMorgan Chase &amp; Co. Chicago, Ill.</i>	Roy S. Roberts <i>Managing Director, Reliant Equity Investors Chicago, Ill.</i>
W. James Farrell <i>Retired Chairman and Chief Executive Officer, Illinois Tool Works, Inc. Glenview, Ill.</i>	Samuel C. Scott III <i>Chairman, President and Chief Executive Officer, Corn Products International Inc. Westchester, Ill.</i>
H. Laurance Fuller <i>Retired Co-Chairman of the Board, BP Amoco, p.l.c. London, United Kingdom</i>	William D. Smithburg <i>Retired Chairman, President and Chief Executive Officer, The Quaker Oats Co. Chicago, Ill.</i>
William A. Osborn <i>Chairman and former Chief Executive Officer, Northern Trust Corporation and its principal subsidiary, The Northern Trust Co. Chicago, Ill.</i>	Glenn F. Tilton <i>Chairman, President and Chief Executive Officer, UAL Corporation and United Air Lines, Inc., a wholly owned subsidiary of UAL Corporation Chicago, Ill.</i>
The Rt. Hon. Lord Owen CH <i>Chairman of Europe Steel, p.l.c. London, United Kingdom</i>	Miles D. White <i>Chairman of the Board and Chief Executive Officer, Abbott</i>
Boone Powell, Jr. <i>Retired Chairman, Baylor Health Care System Dallas, Texas</i>	

## Senior Management

Miles D. White* <i>Chairman of the Board and Chief Executive Officer</i>	Laura J. Schumacher* <i>Executive Vice President, General Counsel and Secretary</i>	Robert B. Hance* <i>Senior Vice President, Diabetes Care</i>
Thomas C. Freyman* <i>Executive Vice President, Finance and Chief Financial Officer</i>	James L. Tyree* <i>Executive Vice President, Pharmaceutical Products</i>	John C. Landgraf* <i>Senior Vice President, Pharmaceuticals, Manufacturing and Supply</i>
Richard W. Ashley* <i>Executive Vice President, Corporate Development</i>	Olivier Bohuon* <i>Senior Vice President, International Pharmaceuticals</i>	John M. Leonard, M.D. <i>Senior Vice President, Pharmaceuticals, Research and Development</i>
John M. Capek, Ph.D.* <i>Executive Vice President, Medical Devices</i>	Thomas F. Chen* <i>Senior Vice President, International Nutrition</i>	Donald V. Patton, Jr.* <i>Senior Vice President, U.S. Nutrition</i>
Holger A. Liepmann* <i>Executive Vice President, Nutritional Products</i>	Edward J. Fiorentino <i>Senior Vice President, Abbott and Executive Vice President, TAP</i>	Mary T. Szela* <i>Senior Vice President, U.S. Pharmaceuticals</i>
Edward L. Michael* <i>Executive Vice President, Diagnostics Products</i>	Stephen R. Fussell* <i>Senior Vice President, Human Resources</i>	

## Corporate Vice Presidents

Carlos Alban <i>Vice President, Pharmaceuticals, Western Europe and Canada</i>	Honey Lynn Goldberg <i>Vice President, Associate General Counsel, Corporate Transactions</i>	D. Stafford O'Kelly <i>Vice President, Molecular Diagnostics</i>
Greg E. Arnsdorff <i>Vice President, Point of Care Diagnostics</i>	Cecilia L. Kimberlin <i>Vice President, Quality, Medical Products</i>	AJ J. Shoultz <i>Vice President, Taxes</i>
Alejandro A. Aruffo, Ph.D. <i>Vice President, Pharmaceuticals Development</i>	Zahir A. Lavji <i>Vice President, Diabetes Care, Commercial Operations</i>	Preston T. Simons <i>Vice President, Information Technology</i>
Catherine V. Babington <i>Vice President, Public Affairs</i>	Elaine R. Leavenworth <i>Vice President, Government Affairs</i>	R. Nicholas Spaulding <i>Vice President, Vascular, Commercial Operations</i>
Michael G. Beatrice, Ph.D. <i>Vice President, Corporate Regulatory and Quality Science</i>	Steven J. Lichter <i>Vice President, Pharmaceuticals, Manufacturing</i>	Eugene Sun, M.D. <i>Vice President, Pharmaceuticals Clinical Development</i>
Charles M. Brock <i>Vice President, Chief Ethics and Compliance Officer</i>	Greg W. Linder* <i>Vice President, Controller</i>	John B. Thomas <i>Vice President, Investor Relations</i>
William J. Chase <i>Vice President, Treasurer</i>	Heather L. Mason <i>Vice President, Pharmaceuticals, Latin America</i>	Michael J. Warmuth <i>Vice President, Hematology Diagnostics</i>
Jaime Contreras <i>Vice President, International Diagnostics</i>	P. Loreen Mershimier <i>Vice President, Integrated Healthcare Policy</i>	Glenn S. Wamer <i>Vice President, Pharmaceuticals, Japan</i>
Thomas J. Dee <i>Vice President, Controller, International Pharmaceuticals</i>	Sean E. Murphy <i>Vice President, Licensing/New Business Development</i>	David E. Wheadon, M.D. <i>Vice President, Pharmaceuticals Regulatory Affairs</i>
Charles D. Foltz <i>Vice President, Vascular Solutions</i>	Daniel W. Norbeck, Ph.D. <i>Vice President, Pharmaceuticals Discovery</i>	Susan M. Widner <i>Vice President, Corporate Marketing</i>

Robert E. Funck  
*Vice President, Internal Audit*

\*Denotes executive officers

Published by Abbott's Investor Relations/Public Affairs Division.  
Corporate Public Affairs: (847) 937-1608; Investor Newslines: (847) 937-7300

The ticker symbol for Abbott's common stock is ABT. It is listed on the New York, Chicago, London and Swiss exchanges. It is traded on the Boston, Philadelphia and National Stock Exchanges, as well as on the NYSE Arca and NASDAQ iM Markets.

**On the cover:** *Abbott Prism* – Arden Cantwell, San Antonio, Texas. Swimming is a big part of 5-year-old Arden Cantwell's life. Unfortunately, so is cancer. As part of Arden's ongoing treatment, she needs regular blood transfusions. With its unique automated processing technology, *Abbott Prism* ensures the safety of her donated blood, allowing Arden to enjoy her swimming lessons.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Herceptin is not a trademark of Abbott Laboratories.

Not all products listed are approved in all countries.

©2008, Abbott Laboratories 120M/4/08

